Atossa Therapeutics Announces Participation in BIO-Europe 2024
Join our CEO for a Fireside Chat on Breast Cancer Prevention
SEATTLE, Oct. 21, 2024 (GLOBE NEWSWIRE) — Atossa Therapeutics, Inc. (NASDAQ: ATOS) (“Atossa” or the “Company”), today announced that Steven Quay, M.D., Ph.D., Chairman and Chief Executive Officer, will join Per Hall, M.D., Professor of Epidemiology at the Department of Medical Epidemiology and Biostatistics at Karolinska Institute, at a fireside chat at BIO-Europe 2024. During the fireside chat, Drs. Quay and Hall will discuss a meaningful approach to combining a state-of-the-art, artificial intelligence (AI)-based risk model with promising emerging therapies that may help prevent breast cancer in high-risk patients. BIO-Europe 2024 is scheduled for November 4-6, 2024, in Stockholm, Sweden. Atossa is a clinical stage biopharmaceutical company developing innovative medicines in areas of significant unmet medical need in oncology with a focus on breast cancer.
Atossa Therapeutics, Inc. is making waves in the biopharmaceutical industry with its innovative approach to breast cancer prevention. By combining cutting-edge AI technology with emerging therapies, the company is paving the way for a more personalized and effective treatment plan for high-risk patients.
The fireside chat at BIO-Europe 2024 promises to shed light on this groundbreaking approach, with Dr. Steven Quay and Dr. Per Hall leading the discussion. Their expertise and insights are sure to provide valuable information for researchers, healthcare professionals, and patients alike.
As Atossa continues to develop new medicines in oncology, particularly in the realm of breast cancer treatment, the future looks promising for those in need of better solutions. Stay tuned for updates on this exciting collaboration and the potential impact it may have on the field of medicine.
How This Announcement Will Affect You:
As a high-risk patient for breast cancer, this announcement is particularly significant for you. The combination of AI-based risk modeling and emerging therapies could provide you with a more targeted and effective prevention strategy. Keep an eye on Atossa Therapeutics’ progress in this area for potential new treatment options tailored to your needs.
How This Announcement Will Affect the World:
The collaboration between Atossa Therapeutics and Dr. Per Hall at the Karolinska Institute has the potential to revolutionize the way breast cancer is prevented and treated on a global scale. By leveraging advanced technology and cutting-edge therapies, this partnership could set a new standard for oncology research and care worldwide.
Conclusion:
Atossa Therapeutics’ participation in BIO-Europe 2024 and the upcoming fireside chat with Drs. Quay and Hall mark a significant milestone in the fight against breast cancer. This innovative approach to combining AI technology with promising therapies holds great promise for high-risk patients and the broader oncology community. Keep an eye on Atossa’s continued progress as they work towards developing groundbreaking treatments for those in need.
